News

Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada

Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching the biosimilar of the pharmaceutical giant's blockbuster psoriasis drug Stelara in Japan, Canada and the European Economic Area.

02/15/2024

3 mid-caps under $20 that Wall Street loves

Picking up where it left off last year, artificial intelligence (AI) data center leader NVIDIA Corporation NASDAQ: NVDA is one. Courtesy of a buyout from Hewlett Packard Enterprise Company NYSE: HPE, Juniper Networks Inc. NYSE: JNPR is another.

01/23/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Alvotech (ALVO) a buy, sell, or hold?

Alvotech (ALVO) can sell. Click on Rating Page for detail.

What is Alvotech's stock price?

The price of Alvotech (ALVO) is 13.37 and it was updated on 2024-05-11 07:00:46.

Is Alvotech (ALVO) overvalued or undervalued?

Currently Alvotech (ALVO) is in undervalued.

News

From:

To:

News
Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Mon, Jan. 22, 2024
Alvotech (ALVO)'s Technical Outlook is Bright After Key Golden Cross From a technical perspective, Alvotech (ALVO) is looking like an interesting pick, as it just reached a key level of support. ALVO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. Thu, Dec. 28, 2023
Alvotech (ALVO) Q3 2023 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q3 2023 Earnings Conference Call November 29, 2023 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director of IR and Global Communications Robert Wessman - Chairman and CEO Anil Okay - Chief Commercial Officer Joel Morales - CFO Conference Call Participants Mikaela Franceschina - Barclays Niall Alexander - Deutsche Bank Thibault Boutherin - Morgan Stanley Operator Welcome to Alvotech's Earnings Call for the First Nine Months of 2023. At this time, all participants are in a listen-only mode. Wed, Nov. 29, 2023
Alvotech to Present at the Jefferies 2023 London Healthcare Conference REYKJAVIK, Iceland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference taking place in London on November 14-16, 2023. Tue, Nov. 07, 2023
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 11–13, 2023. Mon, Sep. 11, 2023

Transcripts

Transcipts Data
Alvotech (ALVO) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Thu, Mar. 21, 2024
Alvotech (ALVO) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Wed, Nov. 29, 2023
Alvotech (ALVO) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Thu, Aug. 31, 2023
Alvotech (ALVO) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Fri, May. 19, 2023
Alvotech (ALVO) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Mon, Mar. 06, 2023
Alvotech (ALVO) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Wed, Nov. 16, 2022
Alvotech (ALVO) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Thu, Sep. 01, 2022

SEC Filings

SEC Filings
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/30/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/25/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/19/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/17/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 03/22/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 03/20/2024
Alvotech (ALVO) - 20-F SEC Filings 03/20/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 03/01/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 02/26/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 02/15/2024
Alvotech (ALVO) - SC 13G/A SEC Filings 02/14/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/29/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/19/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/10/2024
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/03/2024
Alvotech (ALVO) - 6-K/A - Current report SEC Filings 11/30/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/29/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/15/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/14/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/13/2023
Alvotech (ALVO) - EFFECT SEC Filings 10/31/2023
Alvotech (ALVO) - F-3 SEC Filings 10/20/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/12/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/03/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 09/25/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 09/21/2023
Alvotech (ALVO) - 6-K/A - Current report SEC Filings 09/07/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 09/05/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/31/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/01/2023
Alvotech (ALVO) - EFFECT SEC Filings 07/24/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/24/2023
Alvotech (ALVO) - 424B3 SEC Filings 07/24/2023
Alvotech (ALVO) - EFFECT SEC Filings 07/21/2023
Alvotech (ALVO) - POS AM SEC Filings 07/14/2023
Alvotech (ALVO) - F-3 SEC Filings 07/14/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/12/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/29/2023
Alvotech (ALVO) - 424B3 SEC Filings 06/29/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/13/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/06/2023
Alvotech (ALVO) - 424B3 SEC Filings 06/06/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 05/24/2023
Alvotech (ALVO) - 424B3 SEC Filings 05/24/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 05/19/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 05/05/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 05/04/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/20/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/18/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 04/14/2023
Alvotech (ALVO) - 424B3 SEC Filings 04/14/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 03/28/2023
Alvotech (ALVO) - EFFECT SEC Filings 03/17/2023
Alvotech (ALVO) - POS AM SEC Filings 03/13/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 03/01/2023
Alvotech (ALVO) - 20-F SEC Filings 03/01/2023
Alvotech (ALVO) - SC 13G SEC Filings 02/14/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 02/10/2023
Alvotech (ALVO) - 424B3 SEC Filings 02/10/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 02/09/2023
Alvotech (ALVO) - 424B3 SEC Filings 02/09/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 02/07/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/24/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/23/2023
Alvotech (ALVO) - 424B3 SEC Filings 01/23/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/20/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/17/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/11/2023
Alvotech (ALVO) - 424B3 SEC Filings 01/11/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 01/06/2023
Alvotech (ALVO) - 424B3 SEC Filings 01/06/2023
Alvotech (ALVO) - 6-K - Current report SEC Filings 12/22/2022
Alvotech (ALVO) - 424B3 SEC Filings 12/22/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 12/16/2022
Alvotech (ALVO) - 424B3 SEC Filings 12/16/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 12/08/2022
Alvotech (ALVO) - 424B3 SEC Filings 12/08/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 12/01/2022
Alvotech (ALVO) - 424B3 SEC Filings 12/01/2022
Alvotech (ALVO) - SC 13D/A SEC Filings 11/18/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/17/2022
Alvotech (ALVO) - 424B3 SEC Filings 11/17/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 11/16/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/27/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/19/2022
Alvotech (ALVO) - 424B3 SEC Filings 10/19/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/17/2022
Alvotech (ALVO) - 424B3 SEC Filings 10/17/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 10/12/2022
Alvotech (ALVO) - 424B3 SEC Filings 10/12/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 09/23/2022
Alvotech (ALVO) - 424B3 SEC Filings 09/23/2022
Alvotech (ALVO) - EFFECT SEC Filings 09/22/2022
Alvotech (ALVO) - EFFECT SEC Filings 09/22/2022
Alvotech (ALVO) - EFFECT SEC Filings 09/22/2022
Alvotech (ALVO) - 424B3 SEC Filings 09/21/2022
Alvotech (ALVO) - F-1/A SEC Filings 09/14/2022
Alvotech (ALVO) - F-1/A SEC Filings 09/13/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 09/06/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/31/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/29/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/25/2022
Alvotech (ALVO) - S-8 SEC Filings 08/15/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/15/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 08/12/2022
Alvotech (ALVO) - F-1/A SEC Filings 07/27/2022
Alvotech (ALVO) - F-1 SEC Filings 07/22/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/20/2022
Alvotech (ALVO) - SC 13D/A SEC Filings 07/18/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/18/2022
Alvotech (ALVO) - SC 13D/A SEC Filings 07/15/2022
Alvotech (ALVO) - F-1 SEC Filings 07/14/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/14/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/13/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/07/2022
Alvotech (ALVO) - SC 13D SEC Filings 07/05/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 07/05/2022
Alvotech (ALVO) - SC 13D SEC Filings 07/01/2022
Alvotech (ALVO) - SC 13D SEC Filings 06/27/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/23/2022
Alvotech (ALVO) - SC 13G SEC Filings 06/22/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/22/2022
Alvotech (ALVO) - 20-F SEC Filings 06/22/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/21/2022
Alvotech (ALVO) - CERT SEC Filings 06/16/2022
Alvotech (ALVO) - CERT SEC Filings 06/15/2022
Alvotech (ALVO) - 6-K - Current report SEC Filings 06/15/2022
Alvotech (ALVO) - 8-A12B SEC Filings 06/13/2022
Alvotech (ALVO) - 425 SEC Filings 06/09/2022
Alvotech (ALVO) - 425 SEC Filings 06/07/2022
Alvotech (ALVO) - 425 SEC Filings 06/03/2022
Alvotech (ALVO) - 425 SEC Filings 05/31/2022
Alvotech (ALVO) - 425 SEC Filings 05/24/2022
Alvotech (ALVO) - 425 SEC Filings 05/17/2022
Alvotech (ALVO) - SEC STAFF LETTER SEC Filings 05/16/2022
Alvotech (ALVO) - 425 SEC Filings 05/16/2022
Alvotech (ALVO) - EFFECT SEC Filings 05/11/2022
Alvotech (ALVO) - EFFECT SEC Filings 05/11/2022
Alvotech (ALVO) - 425 SEC Filings 05/11/2022
Alvotech (ALVO) - F-4/A SEC Filings 05/10/2022
Alvotech (ALVO) - CORRESP SEC Filings 05/10/2022
Alvotech (ALVO) - 424B3 SEC Filings 05/10/2022
Alvotech (ALVO) - UPLOAD SEC Filings 05/09/2022
Alvotech (ALVO) - F-4/A SEC Filings 05/02/2022
Alvotech (ALVO) - CORRESP SEC Filings 05/02/2022
Alvotech (ALVO) - UPLOAD SEC Filings 04/28/2022
Alvotech (ALVO) - 425 SEC Filings 04/22/2022
Alvotech (ALVO) - F-4/A SEC Filings 04/19/2022
Alvotech (ALVO) - CORRESP SEC Filings 04/19/2022
Alvotech (ALVO) - 425 SEC Filings 04/19/2022
Alvotech (ALVO) - 425 SEC Filings 04/18/2022
Alvotech (ALVO) - UPLOAD SEC Filings 04/12/2022
Alvotech (ALVO) - 425 SEC Filings 04/06/2022
Alvotech (ALVO) - F-4/A SEC Filings 04/04/2022
Alvotech (ALVO) - CORRESP SEC Filings 04/04/2022
Alvotech (ALVO) - UPLOAD SEC Filings 03/30/2022
Alvotech (ALVO) - 425 SEC Filings 03/23/2022
Alvotech (ALVO) - F-4/A SEC Filings 03/14/2022
Alvotech (ALVO) - CORRESP SEC Filings 03/14/2022
Alvotech (ALVO) - 425 SEC Filings 03/08/2022
Alvotech (ALVO) - 425 SEC Filings 02/28/2022
Alvotech (ALVO) - UPLOAD SEC Filings 02/25/2022
Alvotech (ALVO) - 425 SEC Filings 02/23/2022
Alvotech (ALVO) - 425 SEC Filings 02/15/2022
Alvotech (ALVO) - F-4/A SEC Filings 02/07/2022
Alvotech (ALVO) - F-4/A SEC Filings 02/04/2022
Alvotech (ALVO) - CORRESP SEC Filings 02/04/2022
Alvotech (ALVO) - 425 SEC Filings 02/02/2022
Alvotech (ALVO) - SEC STAFF LETTER SEC Filings 01/21/2022
Alvotech (ALVO) - UPLOAD SEC Filings 01/18/2022
Alvotech (ALVO) - 425 SEC Filings 01/18/2022
Alvotech (ALVO) - 425 SEC Filings 01/10/2022
Alvotech (ALVO) - F-4 SEC Filings 12/20/2021

Press Releases

StockPrice Release
Alvotech announces participation at bofa securities healthcare conference 2024 05/02/2024
U.s. commercialization agreement with quallent to drive patient savings with first high-concentration citrate-free interchangeable biosimilar to humira® (adalimumab) 04/30/2024
Alvotech announces topline results from a confirmatory clinical study for avt05, a proposed biosimilar for simponi® (golimumab) 04/24/2024
Alvotech signs u.s. agreement to expand access for newly approved high-concentration interchangeable biosimilar to humira® (adalimumab) 04/19/2024
Alvotech and teva announce u.s. fda approval of selarsdi™ (ustekinumab-aekn), biosimilar to stelara® (ustekinumab) 04/16/2024
Alvotech and teva announce u.s. fda approval of selarsdi™ (ustekinumab-aekn), biosimilar to stelara® (ustekinumab) 04/16/2024
Alvotech hosts audio call for investors at 8:15 am edt on april 3, 2024 04/03/2024
Alvotech hosts audio call for investors at 8:15 am edt on april 3, 2024 04/03/2024
Alvotech announces increase in number of own shares 03/22/2024
Alvotech reports financial results for full year 2023 and provides a business update 03/20/2024
Alvotech announces webcast of full year 2023 financial results on march 21, 2024, at 8:00 am et 03/05/2024
Alvotech announces webcast of full year 2023 financial results on march 21, 2024, at 8:00 am et 03/05/2024
Alvotech appoints interim chief quality officer 02/29/2024
Alvotech accepts offer for the sale of shares for a value of approximately usd 166 million at a purchase price of usd 16.41 (isk 2,250) per share 02/26/2024
Alvotech and teva announce u.s. approval of simlandi® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to humira® 02/23/2024
Alvotech announces expected global market entry dates for avt04 biosimilar to stelara® (ustekinumab) 02/15/2024
Alvotech announces positive top-line results from a pharmacokinetic study for avt03, a proposed biosimilar for prolia® and xgeva® 01/29/2024
Test 01/24/2024
Alvotech provides update on status of biologics license applications for avt02 and avt04 01/19/2024
Stada and alvotech secure approval for uzpruvo, europe's first ustekinumab biosimilar to stelara 01/10/2024
Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate avt06 and reference product eylea® (aflibercept) 01/03/2024
Alvotech announces positive top-line results from a pharmacokinetic study for avt05, a proposed biosimilar for simponi® and simponi aria® 11/29/2023
Alvotech reports financial results for first nine months of 2023 and provides a business update 11/28/2023
Alvotech reports financial results for first nine months of 2023 and provides business update 11/28/2023
Alvotech to report financial results for the first nine months of 2023 on november 28, 2023, and host business update conference call on november 29, 2023, at 8:00 am et 11/21/2023
Alvotech and jamp pharma announce receipt of marketing authorization for jamteki (avt04), the first biosimilar of stelara® (ustekinumab) 11/14/2023
Alvotech and jamp pharma announce receipt of marketing authorization for jamteki™ (avt04), the first biosimilar of stelara® (ustekinumab) 11/14/2023
Stada and alvotech receive positive chmp opinion for europe's first ustekinumab biosimilar to stelara 11/10/2023
Alvotech to present at the jefferies 2023 london healthcare conference 11/07/2023
Alvotech provides update on status of u.s. biologics license application for avt04 10/12/2023
Alvotech and islandsbanki enter into market making agreement for shares trading on nasdaq iceland 10/05/2023
Kashiv biosciences enters into exclusive licensing agreement with alvotech for development & commercialization of a proposed biosimilar to xolair® (omalizumab) 10/03/2023
Alvotech enters into exclusive licensing agreement with kashiv biosciences for development and commercialization of a proposed biosimilar to xolair® (omalizumab) 10/03/2023
Alvotech announces approval in japan of avt04 (ustekinumab), a biosimilar to stelara® 09/25/2023
Alvotech provides u.s. regulatory update on avt02, a high-concentration interchangeable biosimilar candidate to humira® (adalimumab) 09/20/2023
Alvotech to participate in the morgan stanley 21st annual global healthcare conference 09/11/2023
Alvotech announces changes to the leadership team 09/05/2023
Alvotech reports financial results for first six months of 2023 and provides business update 08/30/2023
Alvotech and bioventure announce approval of avt02 (adalimumab) in egypt 08/29/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 08/25/2023
Alvotech to report financial results for the first half of 2023 on august 30, 2023, and host business update conference call on august 31, 2023, at 8:00 am et 08/22/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 08/18/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 08/08/2023
Shareholder action alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 08/03/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 08/01/2023
Investigation action alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 07/31/2023
Alvotech completes $100 million convertible bond private placement 07/31/2023
Investor action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/25/2023
Teva pharmaceuticals and alvotech provide update on strategic biosimilars partnership 07/24/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/21/2023
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of alvotech sa - alvo 07/17/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/17/2023
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of alvotech sa - alvo 07/12/2023
Investigation action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/12/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/10/2023
Investor action alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 07/08/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 07/07/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 07/06/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 07/03/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 06/30/2023
Alvotech provides regulatory update on second biologics license application for avt02 06/28/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 06/20/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 06/15/2023
Alvo, alvow investor news: rosen, trusted investor counsel, encourages alvotech investors to inquire about securities class action investigation - alvo, alvow 06/14/2023
Alvotech and teva secure u.s. license date for avt04, a proposed biosimilar to stelara® 06/12/2023
Alvotech and teva secure u.s. license date for avt04, a proposed biosimilar to stelara® 06/12/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 06/12/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 06/05/2023
Investor action alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 06/02/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 05/31/2023
Alvotech to participate in jefferies healthcare conference 05/31/2023
Investigation action alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 05/29/2023
Rosen, top ranked global counsel, encourages alvotech investors to inquire about securities class action investigation - alvow 05/26/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 05/24/2023
Alvotech and advanz pharma extend strategic partnership to commercialize five proposed biosimilars in europe 05/24/2023
Alvotech reports financial results for first three months of 2023 and provides business update 05/19/2023
Alvotech to participate in morgan stanley annual sustainable finance summit 05/17/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses in excess of $100,000 to contact the firm 05/17/2023
Alvotech issues annual equality report covering 2022 05/15/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 05/12/2023
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of alvotech - alvo 05/10/2023
Alvotech enters into commercialization agreement with polifarma for proposed biosimilar to eylea® (aflibercept) 05/10/2023
Alvotech s.a. annual general meeting to be held june 6, 2023 05/05/2023
Alvotech initiates confirmatory patient study for avt05, a proposed biosimilar for simponi® and simponi aria® 05/04/2023
Alvo, alvow investor news: rosen, skilled investor counsel, encourages alvotech investors with losses in excess of $100k to inquire about securities class action investigation – alvow 05/03/2023
Alvotech to report first quarter 2023 financial results and recent business highlights on may 18, 2023 and host conference call on may 19, 2023 at 8:00 am et 05/03/2023
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of alvotech - alvo 05/02/2023
Shareholder action notice: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 04/24/2023
Alvotech alert: bragar eagel & squire, p.c. is investigating alvotech on behalf of alvotech stockholders and encourages investors to contact the firm 04/19/2023
Sarah tanksley joins board of directors for alvotech hf. and sandra casaca appointed chief quality officer 04/19/2023
Investigation reminder: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 04/19/2023
Investor alert: law offices of howard g. smith announces investigation of alvotech (alvo) on behalf of investors 04/19/2023
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of alvotech - alvo 04/19/2023
Investigation alert: the schall law firm announces it is investigating claims against alvotech and encourages investors with losses to contact the firm 04/18/2023
Glancy prongay & murray llp, a leading securities fraud law firm, announces investigation of alvotech (alvo) on behalf of investors 04/18/2023
The law offices of frank r. cruz announces investigation of alvotech (alvo) on behalf of investors 04/18/2023
Complete response letter received for avt02 biologics license application 04/13/2023
Alvotech provides regulatory update on avt02 biologics license application 04/13/2023
Alvotech provides update on corporate sustainability framework 03/28/2023
Alvotech to present clinical study data for avt04, a proposed biosimilar to stelara®, at 2023 american academy of dermatology (aad) annual meeting 03/17/2023
Alvotech reports financial results for full year 2022 and provides business update 03/01/2023
Alvotech announces webcast of 2022 full year financial results at 8:00 am et on march 2, 2023 02/27/2023
Settlement of alvotech private share placement completed 02/10/2023
Ema confirms acceptance of application for avt04, a proposed biosimilar to stelara® (ustekinumab) 02/09/2023
Alvotech enters into commercialization agreement with advanz pharma for proposed biosimilar to xolair® (omalizumab) 02/06/2023
Alvotech and bioventure announce approval of avt02 (adalimumab) as simlandi in saudi arabia 01/24/2023
Alvotech completes $137 million private share placement 01/23/2023
Alvotech completes $137 million private share placement 01/23/2023
Alvotech and fuji pharma expand partnership adding a new biosimilar candidate 01/13/2023
Alvotech initiates pharmacokinetic study for avt05, a proposed biosimilar for simponi® and simponi aria® 01/11/2023
Alvotech and teva announce acceptance of u.s. biologics license application for avt04, a proposed biosimilar to stelara® (ustekinumab) 01/06/2023
Alvotech and teva announce acceptance of u.s. biologics license application for avt04, a proposed biosimilar to stelara® (ustekinumab) 01/06/2023
Update on u.s. regulatory status of avt02, alvotech's proposed high-concentration, interchangeable biosimilar to humira® 12/22/2022
Correction to total amount in announcement about private placement published 2022-12-16 09:00 gmt to headline field 12/16/2022
Alvotech completes $59.7 million private placement 12/16/2022
Alvotech shares start trading on nasdaq iceland main market 12/08/2022
Alvotech and stada broaden access to hukyndra® adalimumab biosimilar in europe 12/07/2022
Nasdaq iceland approves the request for trading of alvotech's shares on the main market 12/02/2022
Alvotech announces changes to its leadership team 12/01/2022
Alvotech submits its application for admission of the company's shares to trading on nasdaq iceland main market 11/30/2022
Alvotech secures financing facilities of approximately $136 million 11/16/2022
Alvotech secures financing facilities of approximately $136 million 11/16/2022
Alvotech reports financial results for first nine months of 2022 and provides business update 11/16/2022
Alvotech reports financial results for first nine months of 2022 and provides business update 11/15/2022
Alvotech announces australian marketing authorization for avt02, a biosimilar to humira® 11/14/2022
Alvotech to present switching study data for avt02, a proposed biosimilar to humira®, at 2022 american college of rheumatology conference 11/10/2022
Alvotech to report first nine months financial results on november 15, 2022 and host business update conference call at 8:00 am et on november 16, 2022 10/27/2022
Alvotech to participate in upcoming jefferies london healthcare conference in november 10/26/2022
Alvotech and jamp pharma expand exclusive partnership adding two biosimilar candidates for canadian market, bringing new options for patients in specialty care 10/19/2022
Alvotech's partner submits application for marketing approval of first biosimilar candidate in japan 10/17/2022
Alvotech appoints sarah tanksley as chief quality officer 10/11/2022
Alvotech and stada increase access to adalimumab for patients in switzerland with the launch of hukyndra® 09/22/2022
Alvotech reports update on initial avt02 biologics license application 09/05/2022
Alvotech reports first half 2022 financial results and business update 08/31/2022
Alvotech announces corporate sustainability participation and discloses esg data covering 2020 and 2021 08/29/2022
Alvotech initiates confirmatory patient study for avt03, a proposed biosimilar for prolia® and xgeva® 08/25/2022
Alvotech to participate in two upcoming investor conferences in september 2022 08/24/2022
Alvotech to report first six months and second quarter 2022 financial results on august 31, 2022 and host business update conference call at 8:00 am et on september 1, 2022 08/15/2022
Alvotech's board of directors approves plan to prepare for listing on nasdaq main market in iceland 08/12/2022
Alvotech initiates a pharmacokinetic study for avt03, a proposed biosimilar for prolia® and xgeva® 07/20/2022
Alvotech expands its board of directors as part of transition from private to publicly traded company 07/14/2022
Alvotech initiates patient study for avt06, a proposed biosimilar for eylea® 07/07/2022
Alvotech initiates patient study for avt06, a proposed biosimilar for eylea® 07/07/2022
Increase of share capital and creation of treasury share pool to meet obligations with respect to warrants issued by alvotech, the management incentive plan, as well as option to issue shares pursuant to the sepa facility with yorkville 07/05/2022
Alvotech debuts on nasdaq first north growth market becoming first dual-listed icelandic company in united states and iceland 06/22/2022
Supplement to the company description 06/22/2022
Publication of a company description and intended listing on first north iceland 06/21/2022

More Headlines

News
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months of 2023, after U.S. markets close on Wednesday, August 30, 2023. 08/22/2023
Teva Pharmaceuticals and Alvotech expand biosimilars partnership Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market. 07/24/2023
Why Shares of Alvotech Are Jumping Friday Alvotech specializes in biosimilar medicines. The company received a complete response letter from the FDA regarding the manufacturing facility for its Humira biosimilar, AVT02. 06/30/2023
Alvotech: Precarious Cash Position Dilutes Special Situation Opportunity Alvotech has a resolvable CRL. This took down the stock, but when resolved, that could create a quick spike. Ordinarily, this would be an opportunity, except for Alvotech's poor cash position. 06/08/2023
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET REYKJAVIK, Iceland, May 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2023, after U.S. markets close on Thursday, May 18, 2023. 05/03/2023
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders. 04/14/2023
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting Alvotech ( NASDAQ: ALVO ), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the presentation of two posters related to its clinical studies in support of biosimilarity and clinical comparability of Alvotech's ATV04 (ustekinumab) and the reference product Stelara® at the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21 in New Orleans. 03/17/2023
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 REYKJAVIK, Iceland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for full year 2022, after U.S. markets close on Wednesday, March 1, 2023. 02/27/2023
Competition Coming For AbbVie's Blockbuster Humira It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. 02/16/2023
Why Shares of Alvotech Jumped This Week The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe. 12/08/2022
Alvotech (ALVO) Q3 2022 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Benedikt Stefansson - Director of Investor Relations and Global Communication Robert Wessman - Executive Chairman & Founder Anil Okay - Chief Commercial Officer Mark Levick - Chief Executive Officer Joel Morales - Chief Financial Officer Conference Call Participants Mark Bavoso - Morgan Stanley Andrew Baum - Citi Carl Byrnes - Northland Capital Markets Ash Verma - UBS Operator Good day, and thank you for standing by. Welcome to the Alvotech Third Quarter 2022 Earnings Conference Call. 11/16/2022
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference REYKJAVIK, Iceland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 at the American College of Rheumatology (ACR) Convergence Conference, being held in Philadelphia on November 10-14, 2022. 11/10/2022
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022 Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S. markets close on Tuesday, November 15, 2022. 10/27/2022
Alvotech (ALVO) Q2 2022 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q2 2022 Earnings Conference Call September 1, 2022 8:00 AM ET Company Participants Benedict Stephan - Investor Relations Robert Wessman - Executive Chairman & Founder Mark Levick - Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategic Officer Conference Call Participants Tybalt Mornan - Morgan Stanley Karen Marchetti - Northland Jason Guerra - Bank of America Benedict Stephan [Call Started Abruptly] materials and some of our statements that we make today may include forward looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission, and the Nasdaq Iceland Stock Exchange. 09/01/2022
Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022. Representatives of Alvotech will hold two fireside chats: 08/24/2022
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months and second quarter of 2022, after U.S. markets close on Wednesday, August 31, 2022. 08/15/2022

Unlock

ALVO Ratings Summary

ALVO Quant Ranking